Literature DB >> 14590198

Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia.

M Moleski1.   

Abstract

Medical treatment for acute lymphoblastic leukemia (ALL) has improved survival rates to 70% for children currently diagnosed with this disease. Intrathecal (IT) chemotherapy replaced CNS radiation therapy (CRT) for those with a favorable diagnosis as research revealed cognitive deficits associated with CRT. The literature pertaining to the potential adverse intellectual and neurophysiological consequences of IT chemotherapy is reviewed. It is concluded that IT chemotherapy may not be a benign form of treatment, although its effects may be more subtle than those produced by CRT. Future studies implementing more comprehensive test batteries are needed to illuminate these deficits so that remediation may be possible for ALL survivors.

Entities:  

Year:  2000        PMID: 14590198

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  62 in total

1.  Population-based exploration of academic achievement outcomes in pediatric acute lymphoblastic leukemia survivors.

Authors:  Lyndsay A Harshman; Sheila Barron; Anna M Button; Brian J Smith; Brian K Link; Charles F Lynch; Natalie L Denburg
Journal:  J Pediatr Psychol       Date:  2012-01-23

2.  Parent and teacher ratings of attention during a year-long methylphenidate trial in children treated for cancer.

Authors:  Kelli L Netson; Heather M Conklin; Jason M Ashford; Lisa S Kahalley; Shengie Wu; Xiaoping Xiong
Journal:  J Pediatr Psychol       Date:  2010-11-19

3.  Neurodevelopmental functioning in very young children undergoing treatment for non-CNS cancers.

Authors:  Marc H Bornstein; Sara Scrimin; Diane L Putnick; Fabia Capello; O Maurice Haynes; Simona de Falco; Modesto Carli; Marta Pillon
Journal:  J Pediatr Psychol       Date:  2012-02-02

4.  Are the psychological needs of adolescent survivors of pediatric cancer adequately identified and treated?

Authors:  Lisa S Kahalley; Stephanie J Wilson; Vida L Tyc; Heather M Conklin; Melissa M Hudson; Shengjie Wu; Xiaoping Xiong; Heather H Stancel; Pamela S Hinds
Journal:  Psychooncology       Date:  2012-01-25       Impact factor: 3.894

5.  Symptoms of attention-deficit/hyperactivity disorder in long-term survivors of childhood leukemia.

Authors:  Kevin R Krull; Raja B Khan; Kirsten K Ness; Davonna Ledet; Liang Zhu; Ching-Hon Pui; Scott C Howard; Deo Kumar Srivastava; Noah D Sabin; Melissa M Hudson; E Brannon Morris
Journal:  Pediatr Blood Cancer       Date:  2011-01-28       Impact factor: 3.167

6.  Parenting stress and neurocognitive late effects in childhood cancer survivors.

Authors:  Sunita K Patel; Andrew L Wong; Michelle Cuevas; Hillary Van Horn
Journal:  Psychooncology       Date:  2012-10-25       Impact factor: 3.894

Review 7.  Preventing neurocognitive late effects in childhood cancer survivors.

Authors:  Martha A Askins; Bartlett D Moore
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

8.  Growth effects of methylphenidate among childhood cancer survivors: a 12-month case-matched open-label study.

Authors:  Bruce W Jasper; Heather M Conklin; Joanne Lawford; E Brannon Morris; Scott C Howard; Shengjie Wu; Xiaoping Xiong; John Shelso; Raja B Khan
Journal:  Pediatr Blood Cancer       Date:  2009-01       Impact factor: 3.167

9.  The Childhood Cancer Survivor Study-Neurocognitive Questionnaire (CCSS-NCQ) revised: item response analysis and concurrent validity.

Authors:  Kelly M Kenzik; I-Chan Huang; Tara M Brinkman; Brandon Baughman; Kirsten K Ness; Elizabeth A Shenkman; Melissa M Hudson; Leslie L Robison; Kevin R Krull
Journal:  Neuropsychology       Date:  2014-06-16       Impact factor: 3.295

10.  Leukemia-derived exosomes and cytokines pave the way for entry into the brain.

Authors:  Ichiko Kinjyo; Denis Bragin; Rachel Grattan; Stuart S Winter; Bridget S Wilson
Journal:  J Leukoc Biol       Date:  2019-01-31       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.